M
Michael J. Elman
Researcher at Johns Hopkins University
Publications - 78
Citations - 10238
Michael J. Elman is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Visual acuity & Macular degeneration. The author has an hindex of 36, co-authored 72 publications receiving 8783 citations. Previous affiliations of Michael J. Elman include Johns Hopkins University School of Medicine & University of Maryland, Baltimore.
Papers
More filters
Journal ArticleDOI
Randomized Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular Edema
Michael J. Elman,Lloyd Paul Aiello,Roy W. Beck,Neil M. Bressler,Susan B. Bressler,Allison R. Edwards,Frederick L. Ferris,Scott M. Friedman,Adam R. Glassman,Kellee M. Miller,Ingrid U. Scott,Cynthia R. Stockdale,Jennifer K. Sun +12 more
TL;DR: Intravitreal ranibizumab with prompt or deferred laser is more effective through at least 1 year compared with prompt laser alone for the treatment of DME involving the central macula.
Journal ArticleDOI
Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema.
John A. Wells,Adam R. Glassman,Allison R. Ayala,Lee M. Jampol,Lloyd Paul Aiello,Andrew N. Antoszyk,Bambi Arnold-Bush,Carl W. Baker,Neil M. Bressler,David J. Browning,Michael J. Elman,Frederick L. Ferris,Scott M. Friedman,Michele Melia,Dante J. Pieramici,Jennifer K. Sun,Roy W. Beck +16 more
TL;DR: Intravitreous aflibercept, bevacizumAB, or ranibizumab improved vision in eyes with center-involved diabetic macular edema, but the relative effect depended on baseline visual acuity.
Journal ArticleDOI
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial
Emily Y. Chew,Traci E Clemons,John Paul SanGiovanni,Ronald P. Danis,Frederick L. Ferris,Michael J. Elman,Andrew N. Antoszyk,Alan J. Ruby,David H. Orth,Susan B. Bressler,Gary E. Fish,Baker Hubbard,Michael L. Klein,Suresh R. Chandra,Barbara A Blodi,Amitha Domalpally,Thomas R. Friberg,Wai T. Wong,Philip J. Rosenfeld,Elvira Agrón,Cynthia A. Toth,Paul S. Bernstein,Robert Sperdut +22 more
TL;DR: Addition of lutein + zeaxanthin, DHA + EPA, or both to the AREDS formulation in primary analyses did not reduce risk of progression to advanced AMD, but because of potential increased incidence of lung cancer in former smokers, luteIn + zexanthin could be an appropriate carotenoid substitute in the ARedS formulation.
Journal ArticleDOI
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Jeffrey G. Gross,Adam R. Glassman,Lee M. Jampol,Seidu Inusah,Lloyd Paul Aiello,Andrew N. Antoszyk,Carl W. Baker,Brian B. Berger,Neil M. Bressler,David J. Browning,Michael J. Elman,Frederick L. Ferris,Scott M. Friedman,Dennis M. Marcus,Michele Melia,Cynthia R. Stockdale,Jennifer K. Sun,Roy W. Beck +17 more
TL;DR: Treatment with ranibizumab resulted in visual acuity that was noninferior to (not worse than) PRP treatment at 2 years, and may be a reasonable treatment alternative, at least through 1 years, for patients with proliferative diabetic retinopathy.
Journal ArticleDOI
Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt versus Deferred Laser Treatment: 5-Year Randomized Trial Results
Michael J. Elman,Allison R. Ayala,Neil M. Bressler,David J. Browning,Christina J. Flaxel,Adam R. Glassman,Lee M. Jampol,Thomas W. Stone +7 more
TL;DR: Five-year results suggest focal/grid laser treatment at the initiation of intravitreal ranibizumab is no better than deferring laser treatment for ≥24 weeks in eyes with DME involving the central macula with vision impairment.